# US 2023/0265202 A1 · Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265202 A1
- Document ID: US20230265202A1
- Status: Published application
- Kind: A1
- Application number: 17/919,109
- Filed: 2021-04-09
- Published: 2023-08-24
- Earliest claimed: 2020-04-15
- Assignees: Zymeworks Inc.
- Applicants: Zymeworks Inc.
- Inventors: Daniel T. PATTON; Lee FREIBURGER; Thomas SPRETER VON KREUDENSTEIN; David M. MILLS; Gesa VOLKERS; Dunja UROSEV; Zhuang DUAN; Elizabeth HALVORSEN; Harsh PRATAP; Brandon CLAVETTE; Anna VON ROSSUM; Patricia ZWIERZCHOWSKI; Peter Wing Yiu CHAN; Danny CHUI; Sylwia JANCOWSKI; Sukhbir Singh KANG; Grant Raymond Wickman
- Web page: https://patentgrep.com/patent/US20230265202A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are antibody constructs comprising a 4- 1BB binding domain and an anti-Folate Receptor a (FRa) antigen- binding domain, wherein the 4-1BB-binding domain and the FRα antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function. The antibody constructs are used in the treatment of a subject having cancer.

## Claims

### Claim 1

An antibody construct comprising:
a) a first 4-1BB-antigen binding domain derived from an agonistic anti-4-1BB antibody, and
b) a first folate receptor alpha (FRα)-antigen binding domain in scFv format comprising a heavy chain variable domain (VH) sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the VH sequence of antibody 8K22 and comprising the three heavy chain CDR sequences of antibody 8K22 and a light chain variable domain (VL) sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the VL sequence of antibody 8K22 comprising the three light chain CDR sequences of antibody 8K22, and further comprising one or more amino acid modifications in the VH domain and/or in the VL domain of antibody 8K22 that improve the biophysical properties of the antibody construct,
wherein the first 4-1BB-antigen binding domain and the first FRα-antigen binding domain are linked directly or indirectly to a scaffold.

### Claim 2 (depends on 1)

The antibody construct according to claim 1, wherein the one or more amino acid modifications increase the thermal stability of the first FRα antigen-binding domain.

### Claim 3 (depends on 1, 2)

The antibody construct according to claim 1 or 2, wherein the one or more amino acid modifications result in a decrease in the amount of high molecular weight species of the antibody construct during production.

### Claim 4 (depends on 1, 2, 3)

The antibody construct according to any one of claims 1 to 3, wherein the one or more amino acid modifications comprise amino acid substitution at one or more of residues Y67, F83, Y49, and V15 of the VL sequence of antibody 8K22, wherein the numbering of residues is according to the Kabat numbering system.

### Claim 5 (depends on 1, 2, 3, 4)

The antibody construct according to any one of claims 1 to 4, wherein the one or more amino acid modifications comprise insertion of lysine (K) at position 75 of the VH sequence of antibody 8K22, wherein the numbering of residues is according to the Kabat numbering system.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody construct according to any one of claims 1 to 5, wherein the one or more amino acid modifications comprise amino acid substitution at one or more of residues I53, L108, V89, and Q105, in the VH sequence of antibody 8K22 wherein the numbering of residues is according to the Kabat numbering system.

### Claim 7 (depends on 4)

The antibody construct according to claim 4, wherein the one or more amino acid modifications in the VH sequence and/or the VL sequence of 8K22 comprise:
a) F83A or F83D in the VL sequence,
b) V15P or V15T in the VL sequence,
c) F83A in the VL sequence, I48V, A49S, A63V, S73N, and V78L in the VH sequence, and insertion of lysine at residue 75 of the VH sequence,
d) I53 S in the VH sequence,
e) V89T in the VH sequence
f) Q105D or Q105E in the VH sequence,
g) F83A in the VL sequence and L108T in the VH sequence,
h) F83A in the VL sequence and I53S in the VH sequence,
i) F83A in the VL sequence and L108T and I53S in the VH sequence,
j) F83A and Y67S in the VL sequence,
k) F83A and Y67S in the VL sequence, and L108T in the VH sequence, or
1) F83A and Y67S in the VL sequence, and L108T and I53S in the VH sequence.

### Claim 8 (depends on 7)

The antibody construct according to claim 7, wherein the first FRα-antigen binding domain comprises the VH sequence and the VL sequence of variant 31588, 31586, 31594, or 31595.

### Claim 9 (depends on 8)

The antibody construct according to claim 8, wherein the first FRα-antigen binding domain comprises the sequence as set forth in SEQ ID NO:831.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antibody construct according to any one of claims 1 to 9, further comprising a second 4-1BB-antigen-binding domain, linked directly or indirectly to the scaffold.

### Claim 11 (depends on 10)

The antibody construct according to claim 10, wherein the first 4-1BB-antigen-binding domain is different from the second 4-1BB-antigen-binding domain.

### Claim 12 (depends on 10, 11)

The antibody construct according to claim 10 or 11, wherein the first 4-1BB-antigen-binding domain is the same as the second 4-1BB-antigen-binding domain.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The antibody construct according to any one of claims 1 to 12, wherein the first 4-1BB antigen binding domain comprises:
a) a heavy chain variable domain (VH) comprising the three heavy chain complementarity-determining regions (CDRs) of antibody 1G1, and a light chain variable domain (VL) comprising the three light chain CDRs of antibody 1G1,
b) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 5G8, and a light chain variable domain comprising the three light chain CDRs of antibody 5G8, or
c) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1C8, and a light chain variable domain comprising the three light chain CDRs of antibody 1C8.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The antibody construct according to any one of claims 1 to 12, wherein the first 4-1BB-antigen binding domain comprises:
a) a heavy chain variable domain (VH) comprising the three heavy chain CDRs of antibody 1G1 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:46, and a light chain variable domain (VL) comprising the three light chain CDRs of antibody 1G1 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:58,
b) a heavy chain variable domain comprising the three heavy chain CDRs of antibody and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:62, and a light chain variable domain comprising the three light chain CDRs of antibody 5G8 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:64, or
c) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1C8 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:53, and a light chain variable domain comprising the three light chain CDRs of antibody 1C8 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:48.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The antibody construct according to any one of claims 10 to 14, wherein the first 4-1BB-antigen-binding domain and the second 4-1BB-antigen-binding domain are in a Fab format.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The antibody construct according to any one of claims 1 to 15, wherein the scaffold is a dimeric Fc construct having a first Fc polypeptide and a second Fc polypeptide, each Fc polypeptide comprising a CH3 sequence, or wherein the scaffold is a linker or an albumin polypeptide.

### Claim 17 (depends on 16)

The antibody construct according to claim 16, wherein the scaffold is a heterodimeric Fc construct having a first Fc polypeptide that is different from the second Fc polypeptide, and wherein the CH3 sequences of the first Fc polypeptide and the second Fc polypeptide comprise amino acid substitutions that promote the formation of a heterodimeric Fc.

### Claim 18 (depends on 17)

The antibody construct according to claim 17, wherein:
a) one Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392L_T394W;
b) one Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392M_T394W and the other Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V;
c) one Fc polypeptide comprises the amino acid substitutions L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366L_K392M_T394W;
d) one Fc polypeptide comprises the amino acid substitutions L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366L_K392L_T394W; or
e) one Fc polypeptide comprises the amino acid substitutions L351Y_S400E_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366I_N390R_K392M_T394W,
wherein the numbering of residues in the Fc polypeptide is according to the EU numbering system.

### Claim 19 (depends on 16, 17, 18)

The antibody construct according to any one of claims 16 to 18, further comprising one or more amino acid modifications that reduce effector function.

### Claim 20 (depends on 19)

The antibody construct according to claim 19, wherein the one or more amino acid modifications are L234A, L235A and D265S, wherein the numbering of residues is according to the EU numbering system.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The antibody construct according to any one of claims 1 to 20, wherein the first 4-1BB antigen-binding domain is linked to the N terminus of the first Fc polypeptide, and the first TAA antigen-binding domain is linked to the C terminus of the second Fc polypeptide.

### Claim 22 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The antibody construct according to any one of claims 12 to 21, wherein the first 4-1BB antigen-binding domain is linked to the N terminus of the first Fc polypeptide, the first FRα antigen-binding domain is linked to the C terminus of the second Fc polypeptide, and the second 4-1BB antigen-binding domain is linked to the N terminus of the second Fc polypeptide.

### Claim 23 (depends on 10)

The antibody construct according to claim 10, wherein the first 4-1BB antigen-binding domain and the second 4-1BB antigen-binding domain comprise the VH amino acid sequence as set forth in SEQ ID NO:46 and the VL amino acid sequence as set forth in SEQ ID NO:54, and the first FRα-antigen-binding domain comprises the sequence as set forth in SEQ ID NO:831.

### Claim 24 (depends on 23)

The antibody construct according to claim 23, comprising the polypeptide sequences of variant 31588.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The antibody construct according to any one of claims 1 to 24, conjugated to a drug.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A pharmaceutical composition comprising the antibody construct of any one of claims 1 to 25.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

One or more nucleic acids encoding the antibody construct according to any one of claims 1 to 24.

### Claim 28 (depends on 27)

One or more vectors comprising the one or more nucleic acids according to claim 27.

### Claim 29 (depends on 27, 28)

An isolated cell comprising the one or more nucleic acids according to claim 27, or the one or more vectors according to claim 28.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29)

A method of preparing the antibody construct according to any one of claims 1 to 25, comprising culturing the isolated cell of claim 29 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of treating a subject having a cancer, comprising administering to the subject an effective amount of the antibody construct according to any one of claims 1 to 25.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of an effective amount of the antibody construct according to any one of claims 1 to 25 for the treatment of cancer in a subject in need thereof.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of the antibody construct according to any one of claims 1 to 25 in the preparation of a medicament for the treatment of cancer.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The antibody construct according to any one of claims 1 to 25, for use in the treatment of cancer in a subject.

### Claim 35

An antibody construct comprising
a) a first 4-1BB antigen-binding domain derived from an agonistic anti-4-1BB antibody, and
b) a first folate receptor-α (FRα) antigen-binding domain in a Fab format comprising a heavy chain variable domain (VH) comprising the three heavy chain CDR sequences of antibody 8K22 and a light chain variable domain (VL) comprising the three light chain CDR sequences of antibody 8K22,
wherein the first 4-1BB antigen-binding domain and the first FRα antigen-binding domain are linked directly or indirectly to a scaffold.

### Claim 36 (depends on 35)

The antibody construct according to claim 35, wherein the construct comprises the polypeptide sequences of variant 33568, or variant 33569.

### Claim 37 (depends on 35)

The antibody construct according to claim 35, conjugated to a drug.

### Claim 38 (depends on 35, 36)

A pharmaceutical composition comprising the antibody construct of claim 35 or 36.

### Claim 39 (depends on 35, 36)

One or more nucleic acids encoding the antibody construct according to claim 35 or 36.

### Claim 40 (depends on 39)

One or more vectors comprising the one or more nucleic acids according to claim 39.

### Claim 41 (depends on 39, 40)

An isolated cell comprising the one or more nucleic acids according to claim 39 or the one or more vectors according to claim 40.

### Claim 42 (depends on 35, 36, 41)

A method of preparing the antibody construct according to claim 35 or 36, comprising culturing the isolated cell of claim 41 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.

### Claim 43 (depends on 35, 36)

A method of treating a subject having a cancer, comprising administering to the subject an effective amount of the antibody construct according to claim 35 or 36.

### Claim 44 (depends on 35, 36)

Use of an effective amount of the antibody construct to claim 35 or 36 for the treatment of cancer in a subject in need thereof.

### Claim 45 (depends on 35, 36)

Use of the antibody construct according to claim 35 or 36 in the preparation of a medicament for the treatment of cancer.

### Claim 46 (depends on 35, 36)

The antibody construct according to claim 35 or 36, for use in the treatment of cancer in a subject.

### Claim 47

An antibody construct comprising:
a) a first 4-1BB antigen-binding domain derived from an agonistic anti-4-1BB antibody, and
b) a first folate receptor-α (FRα) antigen-binding domain comprising a heavy chain variable domain (VH) comprising the three heavy chain CDR sequences of antibody 2L16 and a light chain variable domain (VL) comprising the three light chain CDR sequences of antibody 2L16,
wherein the first 4-1BB antigen-binding domain and the first FRα antigen-binding domain are linked directly or indirectly to a scaffold.

### Claim 48 (depends on 47)

The antibody construct according to claim 47, wherein the first FRα antigen-binding domain comprises:
a) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:804, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805;
b) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:806, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805,
c) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:807, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805; or
d) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:808, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805.

### Claim 49 (depends on 47, 48)

The antibody construct according to claim 47 or 48, wherein the first FRα antigen-binding domain is in an scFv format.

### Claim 50 (depends on 49)

The antibody construct according to claim 49, wherein the first FRα antigen-binding domain comprises the sequence as set forth in SEQ ID NO:819, SEQ ID NO:820, SEQ ID NO:821, or SEQ ID NO:822.

### Claim 51 (depends on 50)

The antibody construct according to claim 50, wherein the first FRα antigen-binding domain further comprises one or more amino acid modifications in the VH sequence or VL sequence of antibody 2L16 that improve the biophysical properties of the antibody construct.

### Claim 52 (depends on 47, 48)

The antibody construct according to claim 47 or 48, wherein the first FRα antigen-binding domain is in a Fab format.

### Claim 53 (depends on 47, 48, 49, 50, 51, 52)

The antibody construct according to any one of claims 47 to 52, further comprising a second FRα antigen-binding domain.

### Claim 54 (depends on 53)

The antibody construct according to claim 53, wherein the first and second FRα antigen-binding domains are the same.

### Claim 55 (depends on 53)

The antibody construct according to claim 53, wherein the first and second FRα antigen-binding domains are different.

### Claim 56 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55)

The antibody construct according to any one of claims 47 to 55, wherein the first 4-1BB antigen binding domain comprises:
a) a heavy chain variable domain (VH) comprising the three heavy chain CDRs of antibody 1G1, and a light chain variable domain (VL) comprising the three light chain CDRs of antibody 1G1,
b) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 5G8, and a light chain variable domain comprising the three light chain CDRs of antibody 5G8, or
c) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1C8, and a light chain variable domain comprising the three light chain CDRs of antibody 1C8.

### Claim 57 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The antibody construct according to any one of claims 47 to 56, wherein the first 4-1BB antigen-binding domain comprises:
a) a heavy chain variable domain (VH) comprising the three heavy chain CDRs of antibody 1G1 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:46, and a light chain variable domain (VL) comprising the three light chain CDRs of antibody 1G1 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:58,
b) a heavy chain variable domain comprising the three heavy chain CDRs of antibody and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:62, and a light chain variable domain comprising the three light chain CDRs of antibody 5G8 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:64, or
c) a heavy chain variable domain comprising the three heavy chain CDRs of antibody 1C8 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:53, and a light chain variable domain comprising the three light chain CDRs of antibody 1C8 and is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:48.

### Claim 58 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The antibody construct according to any one of claims 47 to 57, further comprising a second 4-1BB antigen-binding domain.

### Claim 59 (depends on 58)

The antibody construct according to claim 58, wherein the first 4-1BB-antigen-binding domain and the second 4-1BB-antigen-binding domain are in a Fab format.

### Claim 60 (depends on 58, 59)

The antibody construct according to claim 58 or 59, wherein the second 4-1BB antigen-binding domain is the same as the first 4-1BB antigen-binding domain.

### Claim 61 (depends on 60)

The antibody construct according to claim 60, wherein the first 4-1BB antigen-binding domain and/or the second 4-1BB antigen-binding domain are in a Fab format.

### Claim 62 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The antibody construct according to any one of claims 47 to 61, wherein the scaffold is a dimeric Fc construct having a first Fc polypeptide and a second Fc polypeptide, each Fc polypeptide comprising a CH3 sequence, or wherein the scaffold is a linker or an albumin polypeptide.

### Claim 63 (depends on 62)

The antibody construct according to claim 62, wherein the scaffold is a heterodimeric Fc construct having a first Fc polypeptide that is different from the second Fc polypeptide, and wherein the CH3 sequences of the first Fc polypeptide and the second Fc polypeptide comprise amino acid substitutions that promote the formation of a heterodimeric Fc.

### Claim 64 (depends on 63)

The antibody construct according to claim 63, wherein:
a) one Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392L_T394W;
b) one Fc polypeptide comprises the amino acid substitutions T350V_T366L_K392M_T394W and the other Fc polypeptide comprises the amino acid substitutions T350V_L351Y_F405A_Y407V;
c) one Fc polypeptide comprises the amino acid substitutions L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366L_K392M_T394W;
d) one Fc polypeptide comprises the amino acid substitutions L351Y_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366L_K392L_T394W; or
e) one Fc polypeptide comprises the amino acid substitutions L351Y_S400E_F405A_Y407V and the other Fc polypeptide comprises the amino acid substitutions T366I_N390R_K392M_T394W,
wherein the numbering of residues in the Fc polypeptide is according to the EU numbering system.

### Claim 65 (depends on 62, 63, 64)

The antibody construct according to any one of claims 62 to 64, further comprising one or more amino acid modifications that reduce effector function.

### Claim 66 (depends on 65)

The antibody construct according to claim 65, wherein the one or more amino acid modifications are L234A, L235A and D265S, wherein the numbering of residues is according to the EU numbering system.

### Claim 67 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The antibody construct according to any one of claims 47 to 66, wherein the first 4-1BB antigen-binding domain is linked to the N terminus of the first Fc polypeptide, and the first FRα antigen-binding domain is linked to the C terminus of the first Fc polypeptide.

### Claim 68 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The antibody construct according to any one of claims 47 to 67, wherein the first 4-1BB antigen-binding domain is linked to the N terminus of the first Fc polypeptide, and the first FRα antigen-binding domain is linked to the C terminus of the second Fc polypeptide.

### Claim 69 (depends on 67, 68)

The antibody construct according to claim 67 or 68, further comprising a second 4-1BB antigen-binding domain linked to the N terminus of the second Fc polypeptide.

### Claim 70 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The antibody construct according to any one of claims 47 to 69, comprising a first 4-1BB antigen-binding domain linked to the N terminus of the first Fc polypeptide, a second 4-1BB antigen-binding domain linked to the N terminus of the second Fc polypeptide, a first FRα antigen-binding domain linked to the C terminus of the first Fc polypeptide and a second FRα antigen-binding domain linked to the C terminus of the second Fc polypeptide.

### Claim 71 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The antibody construct according to any one of claims 47 to 70, comprising a first 4-1BB antigen-binding domain linked to the N terminus of the first Fc polypeptide or to the N terminus of the second Fc polypeptide, a first FRα antigen-binding domain linked to the C terminus of the first Fc polypeptide and a second FRα antigen-binding domain linked to the C terminus of the second Fc polypeptide.

### Claim 72 (depends on 47)

The antibody construct according to claim 47, wherein the construct comprises the polypeptide sequences of any one of variants 31946, 32687, 32686, and 32688.

### Claim 73 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The antibody construct according to any one of claims 47 to 72, conjugated to a drug.

### Claim 74 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A pharmaceutical composition comprising the antibody construct of any one of claims 47 to 73.

### Claim 75 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

One or more nucleic acids encoding the antibody construct according to any one of claims 47 to 72.

### Claim 76 (depends on 75)

One or more vectors comprising the one or more nucleic acids according to claim 75.

### Claim 77 (depends on 75, 76)

An isolated cell comprising the one or more nucleic acid according to claim 75, or the one or more vectors according to claim 76.

### Claim 78 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 77)

A method of preparing the antibody construct according to any one of claims 47 to 73, comprising culturing the isolated cell of claim 77 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.

### Claim 79 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A method of treating a subject having a cancer, comprising administering to the subject an effective amount of the antibody construct according to any one of claims 47 to 73.

### Claim 80 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

Use of an effective amount of the antibody construct according to any one of claims 47 to 73, for the treatment of cancer in a subject in need thereof.

### Claim 81 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

Use of the antibody construct according to any one of claims 47 to 73, in the preparation of a medicament for the treatment of cancer.

### Claim 82 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The antibody construct according to any one of claims 47 to 73, for use in the treatment of cancer in a subject.

### Claim 83

An antibody construct or antigen-binding fragment thereof, that specifically binds to folate receptor-α (FRα), comprising: a heavy chain variable domain (VH) sequence comprising three heavy chain complementarity-determining regions (CDRs) and a light chain variable domain (VL) sequence comprising three light chain CDRs, wherein the heavy chain CDRs and the light chain CDRs are from antibody 2L16.

### Claim 84 (depends on 83)

The antibody construct according to claim 83, wherein the antibody or antigen-binding fragment is or comprises a humanized antibody.

### Claim 85 (depends on 83, 84)

The antibody construct according to claim 83 or 84, comprising:
a) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:804, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805;
b) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:806, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805,
c) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:807, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805; or
d) a VH domain comprising the three heavy chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:808, and a VL domain comprising the three light chain CDRs of antibody 2L16 and having a sequence that is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:805.

### Claim 86 (depends on 83, 84, 85)

The antibody construct according to any one of claims 83 to 85, wherein the antibody construct includes immunoglobulin constant domains, wherein the constant domains are from an IgG1 or a variant thereof, an IgG2 or a variant thereof, an IgG4 or a variant thereof, an IgA or a variant thereof, an IgE or a variant thereof, an IgM or a variant thereof, or an IgD or a variant thereof.

### Claim 87 (depends on 83, 84, 85, 86)

The antibody construct according to any one of claims 83 to 86, wherein the antibody comprises a human IgG1.

### Claim 88 (depends on 83, 84, 85, 86, 87)

The antibody construct according to any one of claims 83 to 87, wherein the antibody or antigen-binding fragment is a monoclonal antibody.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The antibody construct according to any one of claims 83 to 88, wherein the antibody fragment is a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, a scFv fragment, a single domain antibody, or a diabody.

### Claim 90 (depends on 83, 84, 85, 86, 87, 88, 89)

The antibody construct according to any one of claims 83 to 89, conjugated to a drug.

### Claim 91 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

A pharmaceutical composition comprising the antibody construct of any one of claims 83 to 90.

### Claim 92 (depends on 83, 84, 85, 86, 87, 88, 89)

One or more nucleic acids encoding the antibody construct according to any one of claims 83 to 89.

### Claim 93 (depends on 92)

One or more vectors comprising the one or more nucleic acids according to claim 92.

### Claim 94 (depends on 92, 93)

An isolated cell comprising the one or more nucleic acids according to claim 92 or the one or more vectors according to claim 93.

### Claim 95 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 94)

A method of preparing the antibody construct according to any one of claims 83 to 90, comprising culturing the isolated cell of claim 94 under conditions suitable for expressing the antibody construct, and purifying the antibody construct.

### Claim 96 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

A method of treating a subject having a cancer, comprising administering to the subject an effective amount of the antibody construct according to any one of claims 83 to 90.

### Claim 97

Use of an effective amount of the antibody construct according to any one of 83 to 90, for the treatment of cancer in a subject in need thereof.

### Claim 98 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

Use of the antibody construct according to any one of claims 83 to 90, in the preparation of a medicament for the treatment of cancer.

### Claim 99 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

The antibody construct according to any one of claims 83 to 90, for use in the treatment of cancer in a subject.
